Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Revolution Medicines ( (RVMD) ) has issued an announcement.
On June 23, 2025, Revolution Medicines entered into a $2 billion flexible funding agreement with Royalty Pharma to support the global development and commercialization of its RAS(ON) inhibitor portfolio. This strategic financing, consisting of up to $1.25 billion in synthetic royalty and up to $750 million in corporate debt, allows Revolution Medicines to retain full control over product development and commercialization, enhancing its financial resources and strategic options. The agreement is expected to significantly bolster the company’s operations and industry positioning, enabling it to establish new global standards of care for patients with RAS-addicted cancers.
The most recent analyst rating on (RVMD) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on Revolution Medicines stock, see the RVMD Stock Forecast page.
Spark’s Take on RVMD Stock
According to Spark, TipRanks’ AI Analyst, RVMD is a Neutral.
Revolution Medicines has a moderate overall score primarily due to financial challenges such as declining revenues and persistent net losses, common in biotech firms. The technical analysis indicates a bearish trend, and the valuation remains unattractive with a negative P/E ratio. However, the positive strides in the RAS(ON) inhibitor pipeline and strong liquidity position partially offset these challenges, as highlighted in the recent earnings call.
To see Spark’s full report on RVMD stock, click here.
More about Revolution Medicines
Revolution Medicines is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers. The company’s research and development pipeline includes RAS(ON) inhibitors such as daraxonrasib, a RAS(ON) multi-selective inhibitor, and zoldonrasib, a RAS(ON) G12D-selective inhibitor, which are currently in clinical development.
Average Trading Volume: 1,926,077
Technical Sentiment Signal: Buy
Current Market Cap: $7.39B
For an in-depth examination of RVMD stock, go to TipRanks’ Overview page.